Ari J. Rosenberg
Papers
5
Total Citations
95
H-Index
4
About
Ari J. Rosenberg is a leading oncologist and clinical researcher whose work is transforming the treatment of human papillomavirus-positive oropharyngeal cancer (HPV+ OPC). His research focuses on integrating immunotherapy with chemotherapy in the neoadjuvant setting, followed by response-adaptive, de-escalated locoregional therapy. This approach aims to reduce treatment toxicity while preserving excellent survival outcomes. Rosenberg’s landmark OPTIMA II trial (2021, 30 citations) demonstrated the feasibility of using nivolumab, nab-paclitaxel, and carboplatin to guide risk-adapted de-escalation. He further advanced this paradigm with the TARGET-HPV trial (2024, 12 citations), investigating a novel HPV16-specific arenavirus-based immunotherapy. His most-cited work (2024, 45 citations) explores neoadjuvant nivolumab plus chemotherapy with response-adaptive therapy, while his 2025 study on circulating tumor HPV DNA dynamics (7 citations) highlights his commitment to developing non-invasive biomarkers for treatment selection. Rosenberg’s pooled analysis of functional and survival outcomes (2025) underscores the clinical benefit of his de-escalation strategies. His research is pivotal in redefining the standard of care for HPV+ OPC, balancing cure with quality of life.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5